ssddl.JPG

Intravenous Immunoglobulin Market Size, Share & Trends Analysis Report, by Therapeutic Area (Primary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barré Syndrome (GBS), Immune Thrombocytopenic Purpura (ITP), Multifocal Motor Neuropathy (MMN), by Dosage Form, by Type of Immunoglobulin, End User, By Region, Forecasts, 2025-2034

Report Id: 1874 Pages: 180 Published: 14 July 2025 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

Intravenous Immunoglobulin Market Size is valued at USD 13.26 billion in 2024 and is predicted to reach USD 25.46 billion by the year 2034 at a 7.0% CAGR during the forecast period for 2025-2034.

Intravenous Immunoglobulin Market info

Immunoglobulins are glycoprotein molecules produced by plasma or white blood cells. Immunoglobulins serve as a crucial line of defense for the immune system, recognizing and attaching to certain antigens such as bacteria and viruses and aiding in their elimination. Intravenous immunoglobulins are immunoglobulins that are delivered intravenously. Because most patients getting immunoglobulins are in hospitals or clinical settings, intravenous immunoglobulins are the most commonly used mode of administration. This, along with the immunoglobulins' demonstrated efficacy as an effective therapy choice for various immunological illnesses and a lack of training for homecare settings, is driving the Intravenous Immunoglobulin market expansion.

However, tight government rules regarding the use of intravenous immunoglobulin products and the significant risk of side effects associated with them are projected to hamper market expansion. On the contrary, the widespread use of intravenous immunoglobulin for treating various disorders is projected to open up profitable opportunities shortly. 

Recent Developments:

  • In March 2022, Sanofi and Seagen Inc. agreed to work exclusively to discover, develop, and commercialize antibody-drug conjugates (ADCs) targeting up to three cancer targets. Sanofi's unique monoclonal antibody (mAb) technology and Seagen's patented ADC technology will be used in the cooperation. 

Competitive Landscape:

Some of the Intravenous Immunoglobulin market players are:

  • Bio Products Laboratory
  • Biotest
  • China biologics Products Holdings
  • CSL Behring
  • Grifols
  • Kedrion
  • LFB
  • Octapharma
  • Shanghai RAAS Blood products
  • Shire
  • Others Market Players

Market Segmentation:

The Intravenous Immunoglobulin market is segmented into therapeutic area, dosage form, type of immunoglobulin, end user. based on the therapeutic area, the market is segmented into primary immunodeficiency, chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain-Barre syndrome (GBS), immune thrombocytopenic purpura (ITP), multifocal motor neuropathy (MMN). The market is segmented by dosage form into liquid and lyophilized. The market is segmented by type of immunoglobulin into IgG, IgA, IgM, IgE, and IgD. The market is segmented by end users into hospitals, clinics, homecare and other end users.

The Hospital Segment Noticed Growth At A Rapid Rate

The hospital segment is projected to grow rapidly in the global Intravenous Immunoglobulin market because of the extensive hospital network. Furthermore, the rising prevalence of primary immunological deficiencies, hepatitis C, and other disorders has increased the frequency of hospitalizations worldwide, increasing customer demand. Furthermore, hospitals provide prompt reimbursement, treatment, and proper care to many patients, expanding the number of patients.

The North America Intravenous Immunoglobulin Market Holds A Significant Revenue Share In The Region

The North America Intravenous Immunoglobulin market is expected to register the highest market share in revenue shortly. The major factors driving market expansion are the rising level of awareness about goods used to treat immunodeficiency illnesses, expanding clinician interest in these medicines, and rising healthcare expenditure.

Furthermore, the increasing use of IVIG therapies for illness treatment, established healthcare and research infrastructure, and the rapidly growing number of product approvals from the US FDA are expected to contribute to the region's revenue growth. In addition, Asia Pacific is projected to raise at a rapid rate in the global Intravenous Immunoglobulin market due to Emerging economies, rising healthcare spending, and a fast-expanding immunoglobulin market are all factors to consider.

Intravenous Immunoglobulin Market Report Scope:

Report Attribute

Specifications

Market size value in 2024

USD 13.26 Bn

Revenue Forecast in 2034

USD 25.46 Bn

Growth rate CAGR

CAGR of 7.0% from 2025 to 2034

Quantitative units

Representation of revenue in US$ million and CAGR from 2024 to 2031

Historic Year

2021 to 2024

Forecast Year

2025-2034

Report Coverage

The forecast of revenue, the position of the company, the competitive market statistics, growth prospects, and trends

Segments Covered

By Therapeutic Area, By Dosage Form, By Type of Immunoglobulin, By End User and By Region 

Regional scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South Korea; Southeast Asia

Competitive Landscape

Biotest AG, Octapharma AG, LFB Biotechnologies, Grifols SA, CSL Behring, China Biologics Products Inc., Kedrion Biopharma, BDI Pharma Inc., Shanghai RAAS Blood products, Shire and Others

Customization scope

Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing and available payment methods

Explore pricing alternatives that are customized to your particular study requirements.

 

Need Customization
Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Deprecated: stripslashes(): Passing null to parameter #1 ($string) of type string is deprecated in /home/z8nbkwptb7pj/public_html/report-details.php on line 233

Segmentation of Intravenous Immunoglobulin Market-

Intravenous Immunoglobulin Market- By Therapeutic Area

  • Primary Immunodeficiency
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • Guillain-Barré Syndrome (GBS)
  • Immune Thrombocytopenic Purpura (ITP)
  • Multifocal Motor Neuropathy (MMN)

Intravenous Ig

Intravenous Immunoglobulin Market- By Dosage Form

  • Liquid
  • Lyophilized

Intravenous Immunoglobulin Market- By Immunoglobulin

  • IgG
  • IgA
  • IgM
  • IgE
  • IgD

Intravenous Immunoglobulin Market- By End User

  • Hospitals
  • Clinics
  • Homecare
  • Other End Users

Intravenous Immunoglobulin Market By Region-

North America-

  • The US
  • Canada

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa

Rest of Middle East and Africa

 InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Email field cannot be blank!(Use email format)
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
4791
Security Code field cannot be blank!
Frequently Asked Questions

The Celiac Disease Market Size is valued at USD 581.6 Mn in 2023 and is predicted to reach USD 1,195.5 Mn by the year 2031

The Celiac Disease Market is expected to grow at a 9.8% CAGR during the forecast period for 2024-2031.

Amgen, Anokion SA, BioLineRx Ltd, ChemoCentryx, Inc, COUR Pharmaceutical, F. Hoffmann-La Roche Ltd, ImmunogenX, LLC, Innovate Biopharmaceuticals, Take

Treatments, Route Of Administration, End-Users, And Distribution Channels are the key segments of the Celiac Disease Market.

North American region is leading the Celiac Disease Market.